MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
32.08
+1.17
+3.79%
After Hours: 31.89 -0.19 -0.59% 19:38 06/11 EDT
OPEN
30.93
PREV CLOSE
30.91
HIGH
32.45
LOW
30.77
VOLUME
356.43K
TURNOVER
--
52 WEEK HIGH
52.24
52 WEEK LOW
18.14
MARKET CAP
593.55M
P/E (TTM)
1.740
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RIGL last week (0601-0605)?
Weekly Report · 3d ago
Pantginis Reiterates Buy on Rigel, Citing Strengthening Oncology Portfolio and Unchanged $57 Price Target
TipRanks · 06/02 11:17
Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Dow Jones · 06/02 11:12
These 10 small-cap U.S. healthcare giants rank among the market's most attractively valued stocks
Seeking Alpha · 06/01 14:20
Weekly Report: what happened at RIGL last week (0525-0529)?
Weekly Report · 06/01 10:28
Rigel Pharma director Kamil Ali-Jackson disposes of 2,500 common shares worth $72,925
PUBT · 05/28 20:20
Knight Therapeutics launches Tavalisse in Mexico for chronic immune thrombocytopenia
PUBT · 05/27 23:02
Rigel Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Dow Jones · 05/27 15:12
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.